Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious dise… Read more
Revive Therapeutics Ltd (RVVTF) - Total Liabilities
Latest total liabilities as of December 2024: $3.32 Million USD
Based on the latest financial reports, Revive Therapeutics Ltd (RVVTF) has total liabilities worth $3.32 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Revive Therapeutics Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Revive Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Revive Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Revive Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sammakorn Public Company Limited
BK:SAMCO
|
Thailand | ฿3.02 Billion |
|
NuGen Medical Devices Inc
OTCQB:NGMDF
|
USA | $18.85 Million |
|
CGX Energy Inc
PINK:CGXEF
|
USA | $18.74 Million |
|
Kelso Technologies Inc
PINK:KIQSF
|
USA | $1.62 Million |
|
Proodeftiki S.A.
AT:PRD
|
Greece | €9.29 Million |
|
Compremum S.A.
WAR:CPR
|
Poland | zł322.22 Million |
|
Duniec
TA:DUNI
|
Israel | ILA1.16 Billion |
|
ABS-CBN Holdings Corporation
PINK:ABSOF
|
USA | $192.91K |
Liability Composition Analysis (2014–2024)
This chart breaks down Revive Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revive Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revive Therapeutics Ltd (2014–2024)
The table below shows the annual total liabilities of Revive Therapeutics Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $3.40 Million | -5.42% |
| 2023-06-30 | $3.60 Million | -19.35% |
| 2022-06-30 | $4.46 Million | +346.40% |
| 2021-06-30 | $999.68K | +20.22% |
| 2020-06-30 | $831.55K | +158.43% |
| 2019-06-30 | $321.77K | +7.51% |
| 2018-06-30 | $299.30K | -2.98% |
| 2017-06-30 | $308.50K | -62.31% |
| 2016-06-30 | $818.43K | +168.83% |
| 2015-06-30 | $304.44K | +316.49% |
| 2014-06-30 | $73.10K | -- |